Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | CCNK | O75909 | 2/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.35 |
| ▸ | TYMS | P04818 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496079 | 0.84 | CCNT1 (0.43) | SLC6A4 | |
| SCHEMBL25432261 | 0.84 | CCNT1 (0.43) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL3442222 | 0.81 | KDM4E (0.44) | — | |
| SCHEMBL22701213 | 0.79 | MAP2K1 (0.36) | CDC7PIM1CSNK2BCSNK2A1CCNK | |
| SCHEMBL22689349 | 0.76 | CCNK (0.38) | CDC7PIM1CSNK2BCSNK2A1CCNK | |
| SCHEMBL22701228 | 0.76 | PIM1 (0.55) | CDC7PIM1CSNK2BCSNK2A1TYMS | |
| Hydrochloric Acid SCHEMBL3442229 | 0.71 | KDM4E (0.46) | — | |
| Bromide SCHEMBL6643622 | 0.71 | KDM4E (0.46) | — | |
| SCHEMBL6644527 | 0.70 | MAPT (0.41) | CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL3443155 | 0.70 | PARP14 (0.44) | CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227729-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-21 | — | — | US | disclosed |
| EP-3972963-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020234103-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020234103-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227729-A1 | IDENTIFICATION AND USE OF KRAS INHIBITORS | KRAS, NRAS, BRCA1 | CDC7 1265/4885PIM1 839/4885CSNK2B 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.